Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on June 2 announced longer-term follow up from its Phase 1 and pivotal Phase 2 trials of Iclusig (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is 3.56%. On last trading day company shares ended up $6.69. Analysts mean target price for the company is $9.47. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -5.40%.
Red Hat, Inc., (NYSE:RHT) said that Cerner Corp. has successfully leveraged Red Hat Enterprise Linux to enhance the stability and performance of its world-class application hosting services. Red Hat Inc. (NYSE:RHT) shares advanced 1.07% in last trading session and ended the day on $50.85. RHT gross Margin is 84.80% and its return on assets is 6.30%.Red Hat Inc. (NYSE:RHT) quarterly performance is -15.98%.
International Business Machines Corp. (NYSE:IBM) trades at a discount relative to its peers. It is a Dividend Contender, having increased its dividend for nineteen consecutive years at a CAGR of 19%. Its massive share repurchase program is boosting EPS. International Business Machines Corp. (NYSE:IBM) shares moved up 0.21% in last trading session and was closed at $186.37, while trading in range of $185.90 – $187.65. International Business Machines Corp. (NYSE:IBM) year to date (YTD) performance is 0.49%.
On June 4, 2014, Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) learned that the U.S. Food and Drug Administration (“FDA”) granted final approval to Upsher-Smith Laboratories, Inc.’s (“USL”) testosterone gel product, Vogelxo. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) ended the last trading day at $21.75. Company weekly volatility is calculated as 5.57% and price to cash ratio as 14.27.Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) showed a negative weekly performance of -2.82%.
Shares of Cardinal Health Inc. (NYSE:CAH) have been given a consensus rating of “Buy” by the twenty ratings firms that are covering the stock, American Banking and Market News reports. Two equities research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $75.97. Cardinal Health Inc. (NYSE:CAH) net profit margin is 0.40% and weekly performance is 0.20%. On last trading day company shares ended up $70.77. Analysts mean target price for the company is $77.06. Cardinal Health Inc. (NYSE:CAH) distance from 50-day simple moving average (SMA50) is 4.25%.
Leave a Reply